Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis (Q30983016)

22 September 2017

1 reference

title

Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis (English)

1 reference

22 September 2017

0 references

0 references

1 reference

David H Miller

1 reference

22 September 2017

1 April 2004

1 reference

22 September 2017

1 reference

22 September 2017

1 reference

22 September 2017

1 reference

22 September 2017

284-294

1 reference

Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

The role of MRI as a surrogate outcome measure in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Voxel-based morphometry–the methods

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Axonal transection in the lesions of multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Multiple sclerosis lesion quantification using fuzzy-connectedness principles

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Signal intensity on MRI of basal ganglia in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Multiple sclerosis: gadolinium enhancement in MR imaging

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions

28 July 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Thalamic neurodegeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

PET visualization of microglia in multiple sclerosis patients using [11C]PK11195

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Normalized accurate measurement of longitudinal brain change

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Optimizing the association between disability and biological markers in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

One year follow up study of primary and transitional progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Whole brain volume changes in patients with progressive MS treated with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Imaging axonal damage of normal-appearing white matter in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Total brain N-acetylaspartate: a new measure of disease load in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Estimating distributed anatomical connectivity using fast marching methods and diffusion tensor imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging--evidence of Wallerian degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Current classification of mitochondrial disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Primary progressive multiple sclerosis: a 5-year clinical and MR study

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534945

Major differences in the dynamics of primary and secondary progressive multiple sclerosis

25 November 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Multiple sclerosis: serial study of gadolinium-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Relapses and progression of disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Spinal cord atrophy and disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Detection of optic nerve atrophy following a single episode of unilateral optic neuritis by MRI using a fat-saturated short-echo fast FLAIR sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Estimation of metabolite concentrations from localized in vivo proton NMR spectra

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.284

21 January 2018

Identifiers

DOI

10.1602/NEURORX.1.2.284

1 reference

22 September 2017

1 reference

PMC publication ID

534945

22 September 2017

PubMed publication ID

15717029

1 reference

PMC publication ID

534945